Information Provided By:
Fly News Breaks for November 3, 2015
INCY
Nov 3, 2015 | 11:21 EDT
Piper Jaffray analyst Joshua Schimmer raised his price target for Incyte (INCY) to $135 citing the company's "strong" Q3 results and "encouraging" results for the combination of epacadostat with Merck's (MRK) pembrolizumab in solid tumors, including melanoma. He keeps an Overweight rating on the name.
News For INCY From the Last 2 Days
There are no results for your query INCY